Navigation Links
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Date:3/19/2012

reatment groups.

Indacaterol was first approved in November 2009 in the European Union under the brand-name Onbrez® Breezhaler®. It is now approved in more than 80 countries for the treatment of COPD, and is available in more than 30 countries with additional launches planned during 2012.

Important Safety InformationWARNING: ASTHMA-RELATED DEATHLong-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including indacaterol, the active ingredient in Arcapta Neohaler. The safety and efficacy of Arcapta Neohaler in patients with asthma have not been established. Arcapta Neohaler is not indicated for the treatment of asthma.All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication.

Arcapta Neohaler should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition, or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

Arcapta Neohaler should not be used more often, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

Arcapta Neohaler may produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, Arcapta Neohaler should be discontinued immediately and alternative therapy instituted.

Arcapta Neohaler can produce a clinically signific
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushings disease patients in Phase III study
2. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
3. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
4. Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
5. Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
6. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
7. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
8. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
9. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
10. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
11. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Mass. and SYDNEY, July 27, 2011 HeartWare International, Inc. ... second quarter and six months ended June 30, 2011, after ... 4, 2011. A conference call with management is ... August 4, 2011 (being 7:00 am Australian Eastern Standard Time, ...
... July 27, 2011 Varian Medical Systems (NYSE: ... of $0.83 per diluted share in the third quarter of ... year-ago quarter.  Revenues for the quarter were $649 million, up ... on a constant currency basis.  Order backlog at the end ...
Cached Medicine Technology:HeartWare to Report Financial Results for Second Quarter of 2011 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 7
(Date:4/24/2014)... Oregon State University researcher has found a relationship between ... of autism spectrum disorder in very young children. ... to show a direct relationship between motor skills and ... motor skills should be included in treatment plans for ... professor in OSU,s College of Public Health and Human ...
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... University researcher is looking to give exercise enthusiasts the ... latest research shows that a cyber buddy can help. ... for Health Journal , is the first to indicate ... motivator during exercise, a software-generated partner also can be ... isn,t real can still motivate people to give greater ...
(Date:4/23/2014)... that targets an important brain receptor has a dramatic ... relapse behavior, a University at Buffalo animal study has ... may be a novel lead compound for treating cocaine ... research was published as an online preview article in ... the compound, RO5263397, severely blunted a broad range of ...
(Date:4/23/2014)... MD (April 23, 2014) The American Gastroenterological ... the 2014 AGA Research Scholars. The AGA Research ... investigators to develop independent and productive research careers ... Scholar Awards fund an additional year allowing for ... committed to supporting junior faculty who are paving ...
Breaking Medicine News(10 mins):Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:AGA announces 2014 Class of AGA Research Scholars 2
... cells within the lung as they move around and ... the causes of Idiopathic Pulmonary Fibrosis (IPF) a disease ... , IPF fills the delicate gas exchange region of ... Duke University Medical Center researchers have discovered that some ...
... --,Americans, awareness of chronic obstructive pulmonary disease (COPD) is rising, ... doctor about symptoms, according to a new survey by the ... COPD -- the third-leading cause of death in the United ... excess sputum production and a feeling of not being able ...
... HealthDay Reporter , THURSDAY, Dec. 1 (HealthDay ... might encourage better shut-eye: People who met national exercise ... those who didn,t. The research doesn,t confirm that ... there may be another explanation for the apparent connection ...
... A diametric shift in the levels of two proteins ... accumulation of the destructive brain plaque found in Alzheimer,s ... folds others into specific positions to unleash their functions. ... it unleashes the normally dormant BACE1, a protein responsible ...
... 2011Researchers have discovered that over a million people worldwide diagnosed ... fungal infection which is usually left untreated because it is ... new report published today in the Bulletin of the ... and University of Toronto say because the X-ray features and ...
... The American Chemical Society,s (ACS,) 243rd National Meeting & Exposition, ... will be held March 25-29, 2012, in San Diego, ... Convention Center and at area hotels. With more than ... from astronomy to zoology ― the meeting will offer print, ...
Cached Medicine News:Health News:New insights come from tracing cells that scar lungs 2Health News:Many Ignore Symptoms of Lung Disease, Study Finds 2Health News:More Exercise Could Make For Better Sleep: Study 2Health News:More Exercise Could Make For Better Sleep: Study 3Health News:Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation 2Health News:Mistaken identity: New report highlights the global impact of medical misdiagnosis 2
... A wide range of miniTHERM incubators ... the appropriate application solution for their specific ... 18 liters, are compact and extremely space ... typical microwave oven. It is possible to ...
... A wide range of miniTHERM incubators is ... appropriate application solution for their specific requirements. ... liters, are compact and extremely space saving. ... microwave oven. It is possible to stack ...
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc....
Medicine Products: